Search Results

Viome announces it will collaborate with precision health leader, Helomics, to study the link between the gut microbiome and ovarian cancer.

Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that Mark Collins, Ph.D., chief innovation officer of its Helomics subsidiary, recently appeared on DojoLIVE! , a lively podcast and interview forum that brings together a broad roster of technology, business and thought leaders from a wide r

Predictive Oncology Inc. (NASDAQ: POAI) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced continued progress towards by its Helomics subsidiary towards the goal of developing an AI-driven predictive model of ovarian cancer (CancerQuest 2020).

Our new PeDAL fee-for-service offering for Pharmaceutical companies will significantly improve the chances of translating discoveries into the clinic

In addition, Skyline has the right to convert a previous $500,000 loan to Helomics into a further 5% equity stake, which would bring its total ownership to 25%.

Predictive Oncology announces that Helomics CTO Dr. Mark Collins will speak during the scientific session of the conference, and will participate in an invite-only session on the expansion of the UK100K GP to 5 Million genomes.

The deal will use the Helomics D-CHIP platform to develop new approaches for personalized cancer diagnosis and care.

Under the terms of the agreement, Skyline Medical is purchasing preferred stock convertible into 20% of the outstanding common stock of Helomics, representing 20% of the company, in exchange for total consideration of 1.1 million shares of newly issued Skyline common stock.

The joint venture follows a strategic collaboration between Helomics and Skyline announced on November 1, 2017 and represents a deeper partnership between the two companies that is expected to provide Skyline with opportunities to generate revenues from additional markets.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce today that it has completed key data generation milestones in its retrospective study in collaboration with UPMC-Magee Women Hospital, to build AI-driven models of ovarian cancer.